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Abstract
Background: The simultaneous contribution of several etiopathogenic disturbances makes amyotrophic lateral
sclerosis (ALS) a fatal and challenging disease. Here, we studied two different cell therapy protocols to protect both
central and peripheral nervous system in a murine model of ALS.
Methods: Since ALS begins with a distal axonopathy, in a first assay, we performed injection of bone marrow cells
into two hindlimb muscles of transgenic SOD1G93A mice. In a second study, we combined intramuscular and
intraspinal injection of bone marrow cells. Fluorescence-activated cell sorting was used to assess the survival of the
transplanted cells into the injected tissues. The mice were assessed from 8 to 16 weeks of age by means of
locomotion and electrophysiological tests. After follow-up, the spinal cord was processed for analysis of
motoneuron survival and glial cell reactivity.
Results: We found that, after intramuscular injection, bone marrow cells were able to engraft within the muscle.
However, bone marrow cell intramuscular injection failed to promote a general therapeutic effect. In the second
approach, we found that bone marrow cells had limited survival in the spinal cord, but this strategy significantly
improved motor outcomes. Moreover, we also found that the dual cell therapy tended to preserve spinal
motoneurons at late stages of the disease and to reduce microgliosis, although this did not prolong mice survival.
Conclusion: Overall, our findings suggest that targeting more than one affected area of the motor system at once
with bone marrow cell therapy results in a valuable therapeutic intervention for ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset
neurodegenerative disease characterized by a progressive
and selective death of upper and lower motoneurons
(MNs) [1]. Resulting from neuronal loss, patients suffer
progressive atrophy and eventual muscle paralysis that
leads to their death a few years after the onset [2]. As in
other neurodegenerative disorders, most ALS cases are
sporadic; however, several mutations have been identified
in familial cases of ALS (fALS). The most prevalent forms
include mutations encoded in the TARDBP (TDP43) gene,
the hexanucleotide repeat expansions in chromosome-9
open reading frame 72 (C9ORF72) or in the superoxide
dismutase gene (SOD1) [3]. Indeed, the most used experi-
mental model of ALS is a transgenic mouse that overex-
presses a high-copy number of the mutated form of the
human SOD1 gene [4]. This transgenic ALS model mimics
the human pathology, being the most used preclinical tool
to study the disorder and test novel therapies [5]. The
pathogenic mechanisms underlying MN death involve
alterations of multiple molecular mechanisms, including
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: xavier.navarro@uab.cat
1Institute of Neurosciences and Department of Cell Biology, Physiology and
Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain
2Centro de Investigación Biomédica en Red sobre Enfermedades
Neurodegenerativas (CIBERNED), Bellaterra, Spain
Full list of author information is available at the end of the article
Martínez-Muriana et al. Stem Cell Research & Therapy           (2020) 11:53 
https://doi.org/10.1186/s13287-020-1573-6
glutamate-mediated excitotoxicity, defective axonal trans-
port, or activation of neighboring glial cells [6–8]. The
simultaneous disruption of several molecular mechanisms
and cell types raises the difficulty to find an effective treat-
ment. In fact, novel therapies that only target a single
factor have largely failed when translated into human
clinical trials [9]. These failures suggest that more effective
therapeutic approaches should act simultaneously on sev-
eral targets in order to mediate global neuroprotection. In
this way, cell therapy has emerged as a promising way to
target several cells and mechanisms involved in ALS.
Bone marrow cells (BMCs) are easy and fast to isolate
and do not need further manipulation before their trans-
plant, thus being a very convenient source for cell therapy
applications. BMCs are composed by several cell subsets
that include hematopoietic progenitors and a heteroge-
neous population of mesenchymal stromal cells (MSCs)
[10]. Several studies demonstrate that BMC transplantation
ameliorates the progression of diverse neurodegenerative
diseases, including ALS [11–13]. Similarly, previous reports
from our group have revealed that intramuscular injections
of BMCs in mdf/ocd and SOD1G93A mice induce protec-
tion of spinal MNs and improve motor function [14, 15].
The exact molecular mechanisms underlying the beneficial
effects of BMC transplantation are still under debate; how-
ever, they likely involve the immunomodulatory actions of
BMCs and the release of neurotrophic factors [13]. Studies
using BMCs as factor carriers have shown neuroprotection
when transplanted into the spinal cord of SOD1G93A mice
and human patients [12, 16–19]. However, none of these
treatments preserved neuromuscular function and stability
of neuromuscular junctions (NMJs) at suitable levels [20].
Previous studies have attempted to protect both NMJs [15]
and MNs in SOD1G93A mice [12, 21, 22] separately, show-
ing transient mild effects on disease outcomes. Since ALS
begins with a distal axonopathy that precedes MN soma
degeneration [23], in this work, we have attempted to
protect both MN soma, as well as, their terminal axons in
skeletal muscle. Thus, we investigated the effects of the
combined injection of BMCs into hindlimb muscles
and in the spinal cord to protect NMJs and spinal cord
MNs, respectively, in SOD1G93A mice.
Materials and methods
Animals
The animals used in this work were transgenic mice carry-
ing the G93A human SOD1 mutation (B6SJL-Tg [SOD1-
G93A]1Gur) obtained from the Jackson Laboratory (Bar
Harbor, ME, USA) and provided from the colony main-
tained at the University of Zaragoza. For phenotyping,
DNA was extracted from tail samples and further analyzed
by PCR to identify hemizygous transgenic mice and wild-
type littermates. Mice were maintained with food and
water ad libitum at room temperature of 22 ± 2 °C under a
12:12-h light–dark cycle. Endpoint criterium was consid-
ered when animals lost the righting reflex for longer than
30 s. At 8 weeks of age (prior to BMC injection), animals
were electrophysiologically tested to obtain baseline levels.
SOD1G93A females and males were then distributed among
the different experimental groups according to their pro-
genitors, weight, and electrophysiology baseline values in
balanced groups, receiving either BMCs or vehicle.
Bone marrow cells
BMCs were collected from female C57Bl6/J mice or GFP
(green fluorescent protein) mutant mice (C57Bl/6-Tg
[ACTB-EGFP]1Osb/J) [24]. Using the same procedures
already described by our group [14, 15], femurs of these
mice were harvested and the attached muscles and con-
nective tissues were removed. The epiphyseal ends of
the bones were clipped and the marrow was extracted
using intraosseous perfusion with 2ml of Dulbecco’s modi-
fied Eagle medium (DMEM, Gibco). Immediately, BMCs
were centrifuged at 1000 rpm at 4 °C for 5min and concen-
trated to 35,000 cells/μl. For the identification of the cells
after injection, we used GFP-labeled BMCs for long-term
studies or labeled with PKH67 (Sigma), a cell membrane
labeling dye, for the short-term survival experiments.
For transplantation, 8-week-old, prior to MN death and
when axonal degeneration starts [25], SOD1G93A mice
were anesthetized with ketamine (90mg/kg, i.p.) and xyla-
zine (10mg/kg, i.p.). As described previously by our group
[14, 15], for intramuscular injections, a total volume of
14 μl green-labeled BMC suspension (0.5 × 106 BMCs)
was injected into quadriceps femoris (QF) and 7 μl
(0.25 × 106 BMC) into tibialis anterior (TA) muscles
bilaterally using a 27-G needle attached to a Hamilton
syringe. For intraspinal injections, L4-L5 spinal cord
segments were exposed by means of a small laminectomy
and a volume of 5 μl was injected using a glass needle
(30 μm i.d.) coupled to a 10-μl Hamilton syringe. Injec-
tions were made at a perfusion speed of 2 μl/min con-
trolled by an automatic injector (KDS 310 Plus; KD
Scientific), and the tip of the needle was maintained inside
the tissue 3min after each injection to avoid liquid reflux.
Sham-treated SOD1G93A mice received the same volume
injections of vehicle (DMEM).
Functional evaluation
Locomotion, coordination, and muscle strength was
evaluated by rotarod test. Prior to cell injections, all
animals were trained twice per week on the rotating rod
at a constant speed of 14 rpm. All animals used in this
study reached baseline levels (an arbitrary time of 180 s).
After injections, BMC- or sham-treated SOD1G93A mice
were evaluated in the rotarod once per week until 16
weeks of age. The time each animal was able to remain
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on the rotarod turning at a constant speed of 14 rpm
was measured.
Locomotion was further analyzed using a speed-
controlled treadmill (Digigait, Mouse Specifics). To
evaluate the maximum speed that SOD1G93A mice
were able to run at the end-stage of the disease,
animals were placed on the treadmill belt and their
capacity to run with increasing velocities (5, 10, 15,
20, 25, and 30 cm/s) was recorded [26].
Electrophysiological tests were used to evaluate motor
function every 2 weeks from 8 to 16 weeks of age. Nerve
conduction test was performed by stimulating the sciatic
nerve (square pulses of 20-μs duration, Grass S88) through
a pair of needles located percutaneously in the sciatic
notch. Compound muscle action potentials (CMAPs) were
recorded in sciatic nerve muscle targets: TA and gastrocne-
mius medialis muscle (GM) with microneedle electrodes
placed on the muscle [25]. All recordings were amplified
and visualized in a digital oscilloscope (Tektronix 450S).
Measurements of the CMAP amplitude were obtained
from the baseline to the maximal negative peak and the
latency from stimulus to the onset of the first negative
deflection. The recording needles were placed under a
microscope, guided by anatomical landmarks, to ensure
reproducibility of needle location on all animals. During
the tests, the mouse body temperature was maintained
using a controlled heating pad.
Histology
At 16 weeks of age, BMC or SHAM SOD1G93A and
wildtype littermate mice were euthanized with an
overdose of sodium pentobarbital. Immediately, ani-
mals were transcardially perfused with a solution of
4% paraformaldehyde (PFA) in 0.1 M phosphate buffer
(PB) and tissue samples were harvested. Treated and
control muscles were cryopreserved and maintained
in a solution of 30% sucrose with azide in 0.1 M PB
at 4 °C. Spinal cord lumbar segments were harvested
and post-fixed in 4% PFA for 2 h, and then cryopre-
served and maintained at 4 °C with 30% sucrose and
azide in 0.1 M PB.
Lumbar spinal cords were serially cut in transverse
sections of 40-μm thickness using a cryostat (Leica).
Free-floating series of 10 sections were sequentially col-
lected and kept in Olmos solution at − 20 °C. To assess
MN survival, one series was rehydrated and stained for
3 h with a 3.1 mM Cresyl violet solution. Slices were
then washed, dehydrated, and mounted with DPX
(Fluka). L4-L5 MNs were localized by morphology and
size. Only MNs that were polygonal-shaped, larger than
20 μm in diameter and with well-stained nucleoli were
counted. MNs present in the lateral side of both ven-
tral horns were quantified in four serial sections of
the L4-L5 segment [25].
For immunostainings, slides were placed over a hotplate
at 37 °C for 30min. Then, samples were rehydrated in
PBS for 5min and further blocked with a blocking solu-
tion of 5% NDS in PBS-T 0.1% at room temperature.
Once blocked, sections were incubated overnight at
4 °C with anti-Iba1 (Wako, 1:1000) and anti-GFAP
(Dako, 1:1000). Sections were then washed in PBS-T
and further incubated with a specific secondary anti-
body bound to an Alexa-594 or -488 fluorocrom (1:
500, Invitrogen) for 1 h.
Flow cytometry
Fluorescence-activated cell sorting (FACS) was used
to characterize BMCs and to assess the survival of
the transplanted cells into the target tissues. For the
immunophenotyping, BMCs were obtained from fe-
murs of C57Bl6 mice as indicated above. Then, red
blood cells (RBC) were lysed using RBC lysis Buffer
(10x) following the manufacturer’s instructions (Biole-
gend, 420301). Cell suspension was further washed
with FACS buffer (DMEM + 10% FBS) and centri-
fuged twice at 300×g for 10 min at 4 °C. Samples were
further split in several tubes and immunostained. Pri-
mary antibody labeling was performed for 1 h at 4 °C
in FACS buffer with the following conjugated anti-
bodies: mouse lineage antibody cocktail (Lin)-PerCP-
Cy5.5 (1:200, 561317, BD Biosciences), Sca-1-PE-Cy7
(1:200, 561021, BD Biosciences), c-Kit-APC (1:200,
561074, BD Biosciences), and CD34 (1:200, 560238,
BD Biosciences). For the gating strategy, we set up
the cut off based on the corresponding isotypes con-
trol expression (Additional file 1: Figure S1A). For the
analysis, cells were first gated based on size (FSC)
and complexity (SSC) to remove all the debris. Cells
were further gated based on Lin expression to dis-
criminate between progenitors (Lin−) and lineage ma-
ture cells (Lin+). The percentage of mesenchymal
stromal cells (MSC) was calculated by counting all
the Lin−, Sca-1+, c-Kit− and CD34− cells [27].
For the in vivo evaluation of BMC engraftment, ani-
mals were sacrificed and transcardially perfused with 60
ml of 0.9% sterile saline solution, and spinal cords and
hindlimb muscles were rapidly collected and kept in
DMEM. Samples were further mechanically broken up
using a syringe and passed through a 40-μm cell strainer
(BD2 Falcon) with DMEM to disaggregate the cells. To
eliminate debris, the obtained cell suspension was centri-
fuged twice at 300×g for 10 min at 4 °C. Centrifuged cells
were further washed, and the obtained pellet was sus-
pended and fixed in a 1% PFA solution and immediately
analyzed in a FACSCanto flow cytometer (BD Biosci-
ences). Grafted cells were distinguished from tissue resi-
dent cells using the FITC channel where both GFP and
PKH67 dyes are detected.
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Statistics
Data are represented as mean ± SEM and analyzed using
the GraphPad Prism 6 software package (GraphPad Soft-
ware). Locomotion and electrophysiological results were
analyzed using two-way repeated measurements ANOVA
with Tukey post-hoc test for multiple comparisons. For
histological data, two-tailed t-Student test was used. Sur-
vival and forced locomotion results were analyzed using
the Mantel–Cox test. Differences were considered statisti-
cally significant at p < 0.05.
Results
Bone marrow cells immunophenotypic characterization
Adult mouse bone marrow is composed by two main stem
cell lineage populations: hematopoietic stem cells (HSCs)
and mesenchymal stromal cells (MSCs). Previous reports
have demonstrated MSCs therapeutic properties in neuro-
degenerative diseases, including ALS [13]. However, the
MSC population in the mouse bone marrow is quite lim-
ited. Here, using FACS immunophenotyping, we found
that mouse bone marrow is mainly composed by mature
lineage hematopoietic cells (~ 34%, Lin+) and progenitor
cells (~ 55%, Lin−) (Fig. 1a, b). MSCs (Lin−, Sca-1+, c-Kit−
and CD34−), which contain an heterogenous population
of progenitors and stem cells [10], only represented ~ 4%
of the whole bone marrow content (Fig. 1a, b).
BMCs do not improve neuromuscular function in grafted
muscle of SOD1G93A mice
Prior to assess the therapeutic effect of bone marrow cell
injection, we evaluated the survival of the cell grafting
within the muscle (Fig. 2a). We injected bone marrow
green-labeled cells in hindlimbs muscles of SOD1G93A
mice and performed flow cytometry at 7 and 21 days
post-injection (dpi). FACS analysis revealed that green-
labeled BMCs were engrafted within the TA muscle for
at least 3 weeks post-injection (Fig. 2b, c).
Once determined that BMCs were able to survive in
the muscle, we tested their therapeutic effects in the
SOD1G93A mouse model of ALS. Bilateral injections of
BMCs or vehicle were performed in the TA and QF
muscles of SOD1G93A mice at 8 weeks of age (Fig. 3a).
Electrophysiological tests showed that BMC injection
did not improve the CMAP amplitude compared to the
DMEM-injected animals, neither in grafted muscles
(TA) nor in non-injected gastrocnemius medialis (GM)
Fig. 1 Bone marrow cells FACS characterization. a Representative FACS plots showing the gating strategy to quantify the amount of
hematopoietic lineage cells (Lin+), the precursor cells (Lin−) and the MSCs (Lin−, Sca-1+, c-Kit−, CD34−). b Bar plot showing the percentage of each
population within the mouse bone marrow
Martínez-Muriana et al. Stem Cell Research & Therapy           (2020) 11:53 Page 4 of 11
muscles, used as internal control. Besides, bilateral BMC
injections were not enough to improve the overall motor
outcome, neither in the rotarod nor in the treadmill
tests (Fig. 3b). Then, we aimed to know whether BMC
intramuscular injections were able to protect spinal
MNs, as reported in a previous study [14]. We found
that BMC-treated animals had 10% higher number of
surviving MNs compared to SHAM mice, although
this difference did not reach statistical significance
(p = 0.0692) (Fig. 4a–d).
Intraspinal and intramuscular BMC injections preserve
lower motoneuron function in SOD1G93A mice
To further protect spinal MNs, we injected BMCs into
both L4-L5 lumbar spinal cord and hindlimb muscles
(Fig. 5a). Firstly, we assessed the survival of the cells after
spinal injection. Similar to the muscle injection, BMCs
were successfully detected for 1 week after transplantation
(Fig. 5b), but they were not present in the spinal cord
parenchyma at 3 weeks post-injection (Fig. 5c).
Despite having a limited survival, we found that the
combined intramuscular and intraspinal BMC injection
significantly preserved the CMAP amplitude of both
treated and untreated muscles, which are innervated by
spinal cord-grafted segments (Fig. 6a). Indeed, BMC injec-
tion into the spinal cord and muscles further improved
motor outcome in SOD1G93A mice as revealed by better
performance in the rotarod and forced locomotion tests
(Fig. 6b, c). Due to the differences in disease progression
between genders [25], we also performed the dual injec-
tion of BMCs in SOD1G93A male mice. Similar to female
animals, BMC-injected male mice also showed improved
CMAP amplitude of TA muscles, although it was not sta-
tistically significant, probably due to the small sample size
(Fig. 6d). Finally, we assessed the survival of SOD1G93A
mice after the combined BMC injection. Since there were
Fig. 2 Bone marrow cells survival after transplantation in hindlimb muscles of SOD1G93A mice. a Representative drawing showing the first study
design. b, c Representative FACS plots showing green-labeled cells in muscle at 7 days (b) and 21 days (c) after BMC injection in the tibialis
anterior (TA) muscle
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Fig. 3 Effects of bone marrow cells injection in hindlimb muscles of SOD1G93A mice. a Electrophysiological analysis of BMC injection effect in
treated muscles (tibialis anterior) and non-treated muscles (Gastrocnemius medialis) (n = 16 SHAM SOD1G93A vs. 17 BMC-treated SOD1G93A). b Gait
and locomotion analysis by rotarod (n = 15 SHAM SOD1G93A vs. 16 BMCs-treated SOD1G93A) and forced locomotion test (n = 8 SHAM SOD1G93A
vs. 11 BMCs-treated SOD1G93A) after injection of BMCs in hindlimb muscles. Error bars indicate SEM
Fig. 4 Analysis of MN survival after injection of BMCs in hindlimb muscles of SOD1G93A mice. a–c Representative micrographs showing lumbar
spinal MNs in a WT, b SHAM SOD1, or c BMC-treated SOD1 mice. Scale bar = 50 μm. d Quantification of MN sparing after treatment with BMCs
(n = 7 SHAM SOD1G93A vs. 9 BMCs-treated SOD1G93A). Dotted line indicates the average number of MNs in WT mice. Error bars indicate SEM
Martínez-Muriana et al. Stem Cell Research & Therapy           (2020) 11:53 Page 6 of 11
no significant differences between genders, we pooled the
lifespan of males and females. Even though the combined
BMCs-treated animals showed greater preservation of
muscular function at early stages of the disease, the treat-
ment failed to increase mice lifespan (Fig. 6e).
BMC intraspinal and intramuscular injections tend to
preserve spinal MNs and to reduce microglial reactivity
We then investigated whether the combined BMC injec-
tion preserved L4-L5 spinal MNs (Fig. 7a–d). We found
that the dual injection of BMCs increased the percentage
of MNs spared compared to intramuscular injection
(52% intramuscular injection vs. 67% intraspinal and
intramuscular injections) but these results were not sta-
tistically significant. Since non-neuronal cells actively
contribute to MN degeneration, we analyzed the reactiv-
ity of astrocytes and microglial cells in the ventral horn
of lumbar cord segments. Immunolabeling revealed that
the combined BMC injections tend to reduce microglial
but not astroglial immunoreactivity in the ventral horn
of treated mice (Fig. 7e–j).
Discussion
The complex pathophysiology of ALS implies a huge dif-
ficulty for finding successful therapies. Indeed, most pre-
clinical therapies have failed to translate into human
Fig. 5 Bone marrow cells survival after injection into the spinal cord of SOD1G93A mice. a Illustrative image representing the second therapeutic
approach. b, c Representative dotted FACS plots displaying green-labeled BMCs in the lumbar spinal cord at 7 dpi (b) and 21 dpi (c) in
SOD1G93A mice
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trials due to the wide variety of factors involved in this
neurodegenerative disease [9]. For this reason, ap-
proaches that simultaneously act on different targets in-
volved in ALS pathophysiology may provide better
chances for an effective treatment for patients. There-
fore, in this work, we aimed to study different protocols
of BMC transplant in SOD1G93A mice. We found that
BMCs transplanted into two SOD1G93A hindlimb mus-
cles failed to induce general motor improvement and
protection of spinal MNs. However, when these BMC
transplants were combined with injection of BMCs into
the lumbar spinal cord, the therapeutic effects of BMCs
were boosted, resulting in enhanced locomotor skills
and a tendency to preserve spinal MNs but did not pro-
long mice survival.
ALS is a complex neurodegenerative disease where dis-
ruption of multiple cellular functions leads to progressive
loss of MN. At the central level, MNs die due to the alter-
ation of molecular pathways such as autophagy, aggregation
of misfolded proteins, or glutamate-mediated excitotoxicity
[8]. However, MN intrinsic pathways are not the only pro-
cesses involved in MN degeneration. Indeed, different re-
ports point to the contribution of non-neuronal cells,
highlighting the importance of glial and immune responses
as direct players in the death of MNs [28]. In this sense,
peripheral nervous system neuroimmune alterations are
Fig. 6 Evaluation of motor outcomes after intraspinal and intramuscular BMC injection in SOD1G93A mice. a Electrophysiological evaluation of the
compound muscle action potential (CMAP) in BMC-treated muscle (tibialis anterior) and non-treated muscle (Gastrocnemius medialis) in females
(n = 8 SHAM SOD1G93A vs. 12 BMCs-treated SOD1G93A). b Evaluation of the locomotion by Rotarod test and c forced locomotion in the Digigait
(n = 10 SHAM SOD1G93A vs. 12 BMC-treated SOD1G93A). d TA CMAP amplitude in male SOD1G93A mice after BMC treatment (n = 5 per group). e
Evaluation of the maximum lifespan of SOD1G93A mice after combined intraspinal and intramuscular BMC injection (n = 16 SHAM SOD1G93A vs. 18
BMC-treated SOD1G93A). *p < 0.05 vs. SHAM SOD1G93A mice. Error bars indicate SEM
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also found in ALS [29, 30]. In fact, at the peripheral level,
and prior to neuronal degeneration, spinal MNs disconnect
from their target muscles in a process known as “dying-
back” [23, 30]. As a result, the maintenance of the NMJs is
impaired and peripheral axons retract and progressively
degenerate. Due to the complexity of ALS disease, which
involves events that occur in the central and peripheral
systems, as well as in multiple cell types, it is necessary to
develop treatments that can target more than one of these
pathological episodes.
Cell therapy has emerged as a promising approach to
treat multiple disorders due to their potent and diverse
beneficial effects [11–13]. BMC transplantation has
shown promising results in several animal models of
ALS [12, 14, 15, 21]. Since ALS begins with a distal
axonopathy that rapidly progresses retrogradely to the
neuronal soma, we therefore aimed to first protect the
NMJs by transplanting BMCs into the hindlimb muscles
at pre-symptomatic stages of the disease. Here we
showed that BMCs survived for at least 3 weeks after the
injection, which is in accordance with previous reports
revealing the presence of BMCs in the muscle tissue be-
tween 1 and 2months after injection [14, 15]. Similar to
a recent study [21], we found that intramuscular injec-
tion of BMCs did not preserve neuromuscular integrity
nor was translated into general improvement of loco-
motor outcomes. This lack of therapeutic effect may be
explained because of several factors. First, we only
treated QF and TA muscles, which are not the only
effectors involved in locomotion. Second, the limited
grafting of the cells could restrict the therapeutic effects
to the first weeks after injection. We found that BMCs
remained inside the muscle at least for 3 weeks after in-
jections, but they are unlikely to survive for much longer
periods. Although in a previous study we showed that
some cells were still grafted after 2 months post-
injections, the number of cells at that stage was scarce
[14]. Therefore, it is expected that greater beneficial ef-
fects could be achieved by doing multiple BCM injec-
tions over disease progression, as well as, by increasing
the number of grafted muscles.
Despite the limited functional improvement observed
after intramuscular injection of BMCs, when quantifying
the number of MNs in the lumbar spinal cord, we found
a tendency to have higher number of surviving neurons
in BMC-injected mice. In previous reports, we revealed
that BMCs are able to produce GDNF, which can be
retrogradely transported to the neuronal soma and may
account for the 10% increased MN survival observed
after muscle grafting of BMC [14, 15]. However, this
beneficial effect was insufficient to induce extensive
neuronal sparing. Indeed, the functional improvement
found in the previous study in SOD1G93A mice was mild
[15], and we have not been able to reproduce it under
slightly different conditions, such as age at injection,
housing laboratory, and animals colony. A recent report
showed that, whereas BMCs injected intramuscularly or
intravenously did not produce significant improvements
in the SOD1G93A mice, simultaneous injections in the
muscle and intravenously delayed the onset of disease
and decreased microgliosis although this did not pre-
serve lumbar ventral horn MNs [21], For these reasons,
we decided to inject BMCs in the hindlimb muscles and
also into the lumbar spinal cord of SOD1G93A mice. We
found that, in contrast to the skeletal muscles, the sur-
vival of the BMCs within the spinal cord was limited to
just a few days. These results are consistent with previ-
ous reports indicating that survival of grafted cells in the
Fig. 7 Evaluation of MN preservation and glial reactivity in the lumbar spinal cord after combined BMC injection. a, b, c. Representative
photographs of lumbar spinal cord sections showing L4 MNs of a WT, b BMC-treated SOD1G93A mice, and c SHAM SOD1G93A mice. d
Quantification of MN survival after injection of BMCs in spinal cord and hindlimb muscles. Dotted line indicates the mean number of MNs in wild
type mice. e, f, h, i Illustrative micrographs showing immunoreactivity against Iba-1 (green, microglia) or GFAP (red, astrocytes) at 16 weeks of age
in BMCs-treated SOD1G93A mice and SHAM SOD1G93A mice. Quantification of g microglia and j astrocytes after injection of BMCs (n = 6) or
vehicle (n = 4) in SOD1G93A mice. Error bars indicate SEM
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spinal cord is strongly compromised after 1 week [12,
22, 31]. This is likely due to the immune reaction found
within the nervous system of the ALS mice [28]. Since
microglial cells become activated at pre-symptomatic
stages of the disease, they may rapidly phagocytose the
injected cells [29, 32]. Indeed, this immune response
may account for the difference in the survival rate of the
grafted BMCs in the spinal cord as compared to the
skeletal muscle. At peripheral level, infiltration of circu-
lating monocytes occurs even prior to microgliosis [29].
However, they accumulate within the nerve bundles but
not at the NMJs or muscle fibers [30]. This less promin-
ent immune reaction in the muscle could increase the
survival of BMCs. Despite BMCs having a short-time
survival in the spinal cord, injection of BMCs into the
lumbar cord and hindlimb muscles improved the global
motor function of SOD1G93A mice. This new approach
led to ~ 15% greater preservation of spinal MNs at 16
weeks of age as compared to control mice and doubled
the beneficial actions observed after transplantation of
BMCs into the hindlimb muscles. Even though we can-
not rule out the possibility that the beneficial effects
found when combining both injections rely only in the
intraspinal approach, previous reports support that the
combination of different BMC administration routes is
needed to reach therapeutic effects in SOD1G93A mice
[21]. In line with these findings, other studies have re-
vealed that intraspinal BMC injection in SOD1G93A mice
leads to a mild and transitory delay in disease progres-
sion [12, 22], strongly suggesting that our findings are
likely due to the concomitant effects of the intramuscu-
lar and intraspinal injections. This overall therapeutic ef-
fect might be explained by the production of growth
factors, as well as, by the immunomodulatory effects of
the BMCs [21, 33]. Indeed, we found a marked reduction
in microgliosis in the spinal cord of SOD1 mice after
intraspinal injection of BMCs, even though the results
did not reach statistical significance. Previous reports
have revealed that microgliosis is a key factor contribut-
ing to MN death [29, 34]. Therefore, it is not surprising
to observe greater MN survival by reducing microgliosis.
Despite the beneficial actions of this dual transplant-
ation, the survival of mice was not prolonged, which is
likely due to the protective effects of the BMCs at the
site of the transplant (lumbar region) but not in those
CNS areas where they were not grafted.
Conclusion
Overall, our study indicates that combining intramus-
cular injection of BMCs with BMC transplants in the
spinal cord enhanced the therapeutic actions of the
cells and improved motor function and preservation
of spinal MNs. Although this injection protocol is in-
sufficient to increase mice survival, we do not discard
that this could be achieved by repeating the cell injec-
tion at different time-points over the disease progres-
sion, in multiple muscles and areas of the CNS. Thus,
our work suggests that combining muscle and spinal
BMC injections represents an interesting cell therapy
approach for treating ALS.
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